by University of Geneva Targeted inhibition of the DAPKs (Death-associated protein kinase 1 and 3) reduces the proportion of slow-proliferating/senescent-like HuRLow cells and the adaptive response of the whole melanoma-cell population to BRAF inhibition. Credit: UNIGE / Rastine Merat The advent of small-molecule targeted therapies, a decade ago, revolutionized the treatment of metastatic melanoma, provided...
